UNC Lineberger researchers found in a study published in PLOS ONE that the diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for potential anti-cancer benefits. They believe the study shows the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to better predict patient response.
After years of providing spiritual guidance and counseling to UNC patients, many of whom had cancer, the tables turned on hospital chaplain Shay Greene. On Sept. 16, 2011, she was diagnosed with Stage 3 breast cancer. Following a mastectomy, radiation, chemo and breast reconstruction, Greene says she was changed forever. Here, she tells the story of how a pen and paper became the tools that helped her move forward in her own faith and renewed her ministry to others who are going through cancer.
In the journal Cancer Cell, UNC Lineberger researchers report findings of a promising strategy to treat KRAS-mutant pancreatic cancers. Preclinical studies showed promise for using a type of investigational drug that works by inhibiting the protein ERK, the last of a series of signals of a signaling pathway that drives drive abnormal growth of cells with KRAS mutations.
Researchers at UNC Lineberger Comprehensive Cancer Center found that breast cancer patients surveyed about their knowledge of breast reconstruction were only moderately informed about the procedure, and their knowledge of complications was low. The study, published in the journal Annals of Surgery, surveyed 126 breast cancer patients planning to undergo mastectomy at the N.C. Cancer Hospital.